Ci sono presupposti biologici per una diversa risposta al trattamento in relazione al genere? Giulia Marchetti, MD, PhD Dept of Health Sciences- Clinic.

Slides:



Advertisements
Similar presentations
Innate Immunity (part 1) BIOS 486A/586A
Advertisements

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Protease and Polymerase Inhibitors for the Treatment of Hepatitis C
Human immune response to Hepatitis C virus Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital.
Hepatitis C in Minority Populations Andrea E. Reid, MD, MPH Veterans Affairs Medical Center Washington, DC.
The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
(mechanisms of defense against viral, parasitic and fungal infections)
NK cell modulation of T cell responses during viral infection William J. Murphy, Ph.D. Departments of Dermatology and Internal Medicine U.C. Davis School.
Patrizia FARCI. Hepatitis Delta Virus Hepatitis B surface antigen (HBsAg) HDV RNA genome Hepatitis delta antigen (HDAg) 36 nm From HDV: From HBV: From.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Biochemical Markers in the inflammatory response Dr Claire Bethune Consultant Immunologist Derriford Hospital.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
Pattern Recognition Receptors and HBV Infection
DEPARTMENT OF IMMUNOLOGY Chair of Histology and Immunology Medical University of Gda ń sk DEPARTMENT OF IMMUNOLOGY Chair of Histology and Immunology Medical.
Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.
Gui-Qiang Wang Department of Infectious Diseases
Treating HBV Infection: Sustained Remission with Immune control Joseph Sung MD, PhD Department of Medicine and Therapeutics Institute of Digestive Diseases.
Hepatitis C in the Elderly Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL MAY 15,
MICR 304 Immunology & Serology Lecture 6 NK Cells, Lymphocytes Chapter 1.4 –1.17; 2.30 – 2.33 Lecture 6 NK Cells, Lymphocytes Chapter 1.4 –1.17; 2.30 –
Viral mechanisms for subversion of specific immune responses How viruses think?
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
Interferons Cytokine family important for innate immunity against viruses Three classes of IFNs according to the receptor used Type I IFNs essential for.
Differential cytokine responsiveness to toll-like receptor (TLR) ligand stimulation in HIV-1 resistant sex-workers from Nairobi, Kenya T. Blake Ball Ph.D.
Basic Concepts of Immunology Scott Barnum, Ph.D..
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
NIDA Center Genomics Projects Kathie Walters October 2008.
SERUM CYTOKINE EXPRESSION ACCORDING TO LAMIVUDINE THERAPY RESPONSE OF CHRONIC HEPATITIS B VIRUS INFECTION Jungyong Park 1, Younhee Park 1, Young Lan Kim.
The Role of Gut Microbiota in Non-alcoholic Fatty Liver Disease
Modulation of Gene Expression via Disruption Of NF-kB Signaling by a
Human Cytomegalovirus (HCMV)
INNATE IMMUNITY/ MUCOSAL IMMUNOLOGY REVIEW
Host – hepatitis C viral interactions: The role of genetics
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Connections in Behavioral Biology
Immune Responses to HCV and Other Hepatitis Viruses
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Figure 4 Host damage from infection-related inflammatory
Case for androgens Giorgio Arnaldi Clinica di Endocrinologia
The inflammasome in liver disease
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Figure 7 Clinical options for HCC therapy
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Figure 4 Combination immunotherapeutic approaches with imatinib
Roles for Chemokines in Liver Disease
Volume 153, Issue 5, Pages e2 (November 2017)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Volume 140, Issue 3, Pages e2 (March 2011)
Volume 53, Issue 4, Pages (October 2010)
Volume 68, Issue 3, Pages (March 2018)
Figure 6 Innate lymphoid cells in liver inflammation
Key airway signaling pathways induced by respiratory viruses.
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C
Volume 138, Issue 3, Pages e3 (March 2010)
A View to Natural Killer Cells in Hepatitis C
Multiple Sclerosis is a neurological, immune-mediated disorder
Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to.
Tetsuo Takehara, Norio Hayashi 
Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments  László Maródi, MD, PhD, Jean-Laurent.
Host – hepatitis C viral interactions: The role of genetics
Signal transduction pathways and activation of the innate immune response. Signal transduction pathways and activation of the innate immune response. In.
Treatment effectiveness by era.
Hematopoietic stem cell transplantation in HCV-infected patients
Presentation transcript:

Ci sono presupposti biologici per una diversa risposta al trattamento in relazione al genere? Giulia Marchetti, MD, PhD Dept of Health Sciences- Clinic of Infectious Dis- University of Milan, San Paolo Hospital, Milano HCV e Donne

Today’s outline  Response to Interferon-based anti HCV therapy: any role for hormonal-mediated inflammatory milieu?  Any reason to think of gender-based differences in DAA therapy?

Higher rates of SVR to interferon- based therapy according to gender? Manns MP et al. Lancet 2001; McHutchinson JG et al. NEJM 2009…….

Hayashi J et al. Arch Intern Med 1998; also: Floreani A et al. Eur J Gastroenterol Hepatol HCV+ patients (199 men; 112 women)

Men Women Hayashi J et al. Arch Intern Med 1998; also: Floreani A et al. Eur J Gastroenterol Hepatol 2011 Higher rates of SVR to IFN-a in women <40 yo

Effect of sex on SVR related to reproductive status/hormonal asset?

Risk factors of severe fibrosis Villa E et al. Gastroenterology women CHC

Villa E et al. Gastroenterology 2011 Risk factors of severe necroinflammation

Villa E et al. Gastroenterology 2011 Risk factors of SVR failure (442 women CHC)

Effect of sex on SVR is related to different (gender-related) immunologic asset?

Pro-inflammatory milieu in HCV+ patients according to sex and menopause Only in menopausal women baseline IL-6 correlated with higher necroinflammation (OR 3.571; 95%CI , p=.004) Villa E et al. Gastroenterology 2011

Increased pro-inflammatory milieu after the onset of menopause Villa E et al. Gastroenterology 2011 TNF-a, 3 yrs pre- menopause TNF-a, 2 yrs post-menopause

Post-menopausal G1 non-responder TNF-a

Intrahepatic TNF-a substantially affects response to IFN-based anti-HCV therapy Predictors of SVR – Multivariable analysis Taliani G et al. Gastroenterology CHC patients

And TNF-a in the periphery….. Neuman MG et al. Clin Biochem CHC patients

HCV signalling Gale et al. Nature 2005 ss-RNA and ds-RNA PAMP: Pathogen- associated molecular patterns

HCV attenuates IFN signalling Gale et al. Nature 2005 SOCS: suppressor of cytokine signalling Liver toxins Cytokines (TNF-a, IL-6…)

Higher SCOCS-3 protein expression in HCV non non-responder vs responder Non responderResponder HCV-negative Walsh MJ et al. Gut 2006

SOCS-3 gene expression is associated with non- response to IFN-a therapy Persico M Hepatology G1b CHC patients

Gene expression of SOCS3 in non-transformed PBMC from HCV+ NR vs SVR Persico M Hepatology 2007

Walsh MJ et al. Gut 2006

Post-menopausal G1 non-responder TNF-a SOCS3

Menopausal women (might) have resistance to IFN-based therapies through hepatic pro- inflammatory milieu

Increased pro-inflammatory cytokines following surgical menopause is reversed by estrogen therapy Pfeilschifter J et al. Endocrinol Rev 2002

Bone marrow cultures: cytokine production in SN Pfeilschifter J et al. Endocrinol Rev 2002

Adjuvant therapy with raloxifene (selective estrogen receptor modulator) improves response to antiviral therapy Furusyo N et al. J Hepatol CHC post- menopausal women

Is the effect of sex less relevant with direct-acting antivirals? i.e. a less-relevant question from a clinical standpoint; still an interesting question

NK cells constitute the main innate immune cell population in the liver Spengler – Clin Science 2007

The interaction between HCV and the host weakens innate immunity in the liver: Inhibition of TLR pathways Counteraction of type1 IFNs Inhibition of NK cells Impaired trafficking of DC Acute HCV infection- innate immunity

NK cells are a crucial component of HCV-specific response

NK Cells Constrict HCV Replication Adapted from Balagopal, CROI 2015

NK Cells Constrict HCV Replication via NKG2D Adapted from Balagopal, CROI 2015

In chronic HCV NK cells are activated, polarized toward cytotoxicity and deficient IFN-g production (functional dychotomy)

Mondelli M Gastroenterology 2015

Viral cure ≠ immunologic cure

NK cells upon DAA?

NK phenotype “normalization” 13 G1b NR to Peg- IFN/Riba NR, DCV/ASV Serti E et al. Gastroenterology 2015

NK function “normalization” Serti E et al. Gastroenterology G1b NR to Peg- IFN/Riba NR, DCV/ASV

Mondelli M Gastroenterology 2015 Viral cure = immunologic cure

Racial- and gender-related differences in Natural Killer (NK) cell populations may explain altered natural history and treatment responses NKp46 receptor: - Major human NCR involved in NK cell cytotoxicity - Significant role in anti-tumor immunity - Important for antiviral immunity (influenza virus, CMV, HPV- 16) - Up-regulation in response to IFN-α treatment is predictive of SVR

Higher NKp46 in females and Caucasians Healthy uninfected controls: 29 African-American (AA; 55% male); 29 Caucasian- American (CA; 48% male) Golden-Mason L Hepatology 2012

NKp46 expression is associated with increased expression of killing genes/proteins and higher induction of degranulation

NKp46 expression is associated with increased antiviral (HCV) NK activity

HCV-infected hepatocytes demostrate a cell surface pattern of staining for NKp46 ligand Immunological findings corroborate epidemiological data that both race and gender are associates with spontaneous recovery from HCV infection

Differences in NK function and phenotype in HCV+ women versus men? NK cells in DAA non-responders?

Thanks  Esther Merlini  Camilla Tincati  Giusi M Bellistrì  Javier Sanchez-Martinez  Matteo Basilissi  Antonella d ’ Arminio Monforte ICONA Foundation Laboratory at the Clinic of Infectious Dis- Dept of Health Sciences, Univ of Milan (S Paolo Hospital) Clinica di Malattie Infettive e Tropicali, Università di Brescia- Paola Nasta, Francesca Gatti, Giampiero Carosi Malattie Infettive, Ospedale Niguarda Massimo Puoti Pathology Unit, San Paolo Hospital Paola Braidotti Delfina Tosi Federica Savi Solange Romagnoli Gastroenterology Unit, San Paolo Hospital Benedetto Mangiavillano